Christopher Gagliardi
Principal @ Sanofi Ventures
Boston, United States
Christopher Gagliardi is a Series B investor at Sanofi Ventures in Boston focused on Biotechnology and Health Care. Christopher Gagliardi is based out of Boston, Massachusetts, and is the Principal of Sanofi Ventures and Board of Director of Lifordi Immunotherapeutics. Christopher Gagliardi attended the University of North Carolina at Chapel Hill.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Christopher Gagliardi invests in
Stages Christopher Gagliardi invests in
Countries Christopher Gagliardi invests in
Investment Focus
Industry
- Biotechnology 5 (50%)
- Health Care 3 (30%)
- Therapeutics 3 (30%)
- Pharmaceutical 2 (20%)
- Medical 1 (10%)
Stage
- Series B 3 (30%)
- Series C 2 (20%)
- Seed 1 (10%)
- Series D 1 (10%)
- Funding Round 1 (10%)
Country
- United States 4 (40%)
- Denmark 1 (10%)
- Australia 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M / Series D / Jul 15, 2026 | |
QuantX Biosciences
|
QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products. | $85M / Series B / Feb 09, 2026 | |
Lifordi Immunotherapeutics
|
Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders. | $42M / Venture - Series Unknown / Nov 19, 2025 | |
|
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $112M / Series C / Feb 03, 2025 | |
Sudo Biosciences
|
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $30M / Series B / Feb 13, 2024 | |
|
Sudo Biosciences
|
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $116M / Series B / Dec 20, 2023 | |
Minervax
|
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.4M / Oct 11, 2023 | |
|
Minervax
|
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M / Series C / Dec 15, 2022 | |
|
Minervax
|
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $52M / Series B / Dec 15, 2020 | |
i2o Therapeutics
|
i2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies traditionally limited to injections. Using an innovative ionic liquid technology, it leverages the benefits of protecting the drug cargo while also transiently enhancing permeation across the epithelial lining when administered orally. i2o isfocused on creating the next generation of oral peptide and protein-based therapies.The company was founded in 2019 and based in Saratoga, California. | $4M / Seed / Apr 09, 2020 |
Co-Investors
About Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi. We have the ability to seed and to lead financings in early-stage companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. Among these areas are rare diseases, oncology, immunology and inflammation, vaccines, potentialcures in other core areas of Sanofi’s business footprint, and digital health and data science solutions.
Sanofi Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Christopher Gagliardi
Principal
|
|||
Alan Walts
Managing Director
|
|||
Alba Zurriaga Carda
Director of Investments
|
|||
Charles Thyne
Industrial Operations
|
|||
Cris De Luca
Partner, Digital Investments, Sanofi Ventures
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Christopher Gagliardi invest in?
Christopher Gagliardi invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Christopher Gagliardi last invest?
The most recent investment recorded for Christopher Gagliardi closed in Jul 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
